Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Apr-Jun;5(2):46-8.
doi: 10.4103/2231-0770.154199.

Sorafenib induced acral pigmentation: A new entity

Mrinal Gupta  1 , Heena Gupta  1 , Anish Gupta  1
Affiliations
Case Reports

Sorafenib induced acral pigmentation: A new entity

Mrinal Gupta et al. Avicenna J Med. 2015 Apr-Jun.

Abstract

Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoacanthomas, squamous cell carcinomas and eruptive melanocytic naevi. We report a case of asymptomatic hyperpigmentation of the palms and soles in a patient receiving Sorafenib therapy for advanced renal cell carcinoma, in the absence of features of classic HFS, which has not been previously reported in the literature.

Keywords: Acral pigmentation; Sorafenib; hand foot syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Sorafenib induced pigmentation over the palms and soles
See this image and copyright information in PMC

References

    1. Uhlenhake EE, Watson AC, Aronson P. Sorafenib induced eruptive melanocytic lesions. Dermatol Online J. 2013;19:18184. - PubMed
    1. Sil A, Das NK. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma. Indian J Pharmacol. 2014;46:334–6. - PMC - PubMed
    1. Gole P, Madke B, Khopkar U, Kumar P, Noronha V, Yadav M. Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist. Indian Dermatol Online J. 2014;5:89–91. - PMC - PubMed
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. - PubMed
    1. The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala Monitoring Centre; 2005. [Last accessed on 2014 Nov 21]. Available from: http://www.who-umc.org/graphics/4409.pdf .

Publication types